Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has shared an announcement.
On December 1, 2025, Apimeds Pharmaceuticals US, Inc. announced a merger with MindWave Innovations Inc, combining Apimeds’ biopharmaceutical innovation with MindWave’s digital asset financial technology. This merger aims to create a diversified entity that integrates high-growth biotechnology and institutional digital-treasury capabilities, supported by a $100 million PIPE to advance clinical programs and expand digital asset infrastructure. The merger is expected to drive long-term value and maximize stockholder returns by leveraging the strengths of both companies in their respective industries.
More about Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. Its lead product candidate, Apitox, is in late-stage clinical development for treating knee osteoarthritis. MindWave Innovations Inc is a leading provider of institutional Digital Asset Treasury solutions, specializing in Bitcoin treasury infrastructure and AI-driven yield capabilities.
Average Trading Volume: 107,272
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.8M
For an in-depth examination of APUS stock, go to TipRanks’ Overview page.